US$ 23.22
glp 1 hormone deficiency Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression | Pharmacological Reports GLP-1 Agonists In Obesity
Description
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, et al

2022 Apr;13(4):749

Front Neurosci 2013;7:71

The FLOW study was dedicated to exploring the effects of semaglutide against the progression of kidney damage in individuals with type 2 diabetes and albuminuric CKD [13]: during a median of 3.4 years, semaglutide improved a composite outcome of kidney failure
